{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:03:55Z","timestamp":1784779435426,"version":"3.55.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is the second-highest cause of cancer-related incidence and the fifth-highest cause of cancer mortality in males. Prostate cancer is a heterogeneous disease with a wide spectrum of clinical behaviour, ranging from indolent to highly aggressive. Molecular approaches, such as genomic testing, can augment existing clinical risk stratifications and tailor management to the individual. Genomic tests that sample biopsy or surgical tissue can provide a molecular risk assessment and identify actionable therapy targets. Liquid biopsy, while still emerging, may provide a non-invasive alternative to tissue tests and enable longitudinal monitoring of tumour status. We first discuss the molecular landscape of prostate cancer, before providing a detailed overview of the molecular approaches available for early detection and prognostication. Furthermore, methodological considerations and barriers towards clinical implementation for these tests are discussed, highlighting areas of future research.<\/jats:p>","DOI":"10.1007\/s10555-026-10357-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:33:58Z","timestamp":1784777638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5118-5469","authenticated-orcid":false,"given":"Angela","family":"Yee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7037-7378","authenticated-orcid":false,"given":"Jim","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-3203","authenticated-orcid":false,"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-7347","authenticated-orcid":false,"given":"Akash","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-5896","authenticated-orcid":false,"given":"Euan J.","family":"Rodger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-2248","authenticated-orcid":false,"given":"Aniruddha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"3","key":"10357_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., et al. (2022). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"10357_CR2","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1097\/ju.0000000000001531","volume":"205","author":"D Pierre-Victor","year":"2021","unstructured":"Pierre-Victor, D., Pinsky, P. F., Miller, E., & Parnes, H. (2021). Other and all-cause mortality among men diagnosed with prostate cancer in the PLCO trial. Journal of Urology, 205(5), 1372\u20131378. https:\/\/doi.org\/10.1097\/ju.0000000000001531","journal-title":"Journal of Urology"},{"issue":"1","key":"10357_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12957-025-03733-1","volume":"23","author":"F Chu","year":"2025","unstructured":"Chu, F., Chen, L., Guan, Q., Chen, Z., Ji, Q., Ma, Y., et al. (2025). Global burden of prostate cancer: Age-period-cohort analysis from 1990 to 2021 and projections until 2040. World J Surg Oncol., 23(1), 98. https:\/\/doi.org\/10.1186\/s12957-025-03733-1","journal-title":"World J Surg Oncol."},{"issue":"7","key":"10357_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJ Bell","year":"2015","unstructured":"Bell, K. J., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer, 137(7), 1749\u20131757. https:\/\/doi.org\/10.1002\/ijc.29538","journal-title":"International Journal of Cancer"},{"issue":"12","key":"10357_CR5","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/ijc.29408","volume":"137","author":"JL Jahn","year":"2015","unstructured":"Jahn, J. L., Giovannucci, E. L., & Stampfer, M. J. (2015). The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. International Journal of Cancer, 137(12), 2795\u20132802. https:\/\/doi.org\/10.1002\/ijc.29408","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10357_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/his.13712","volume":"74","author":"A Matoso","year":"2019","unstructured":"Matoso, A., & Epstein, J. I. (2019). Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology,74(1), 135\u2013145. https:\/\/doi.org\/10.1111\/his.13712","journal-title":"Histopathology"},{"issue":"1","key":"10357_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-021-02230-y","volume":"20","author":"SWD Merriel","year":"2022","unstructured":"Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., et al. (2022). Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Medicine, 20(1), 54. https:\/\/doi.org\/10.1186\/s12916-021-02230-y","journal-title":"BMC Medicine"},{"issue":"2","key":"10357_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.biotechadv.2016.11.009","volume":"35","author":"S Sharma","year":"2017","unstructured":"Sharma, S., Zapatero-Rodr\u00edguez, J., & O\u2019Kennedy, R. (2017). Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnology Advances, 35(2), 135\u2013149. https:\/\/doi.org\/10.1016\/j.biotechadv.2016.11.009","journal-title":"Biotechnology Advances"},{"issue":"3","key":"10357_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey, B., Rosenkrantz, A. B., Haider, M. A., Padhani, A. R., Villeirs, G., Macura, K. J., et al. (2019). Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. European Urology, 76(3), 340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"European Urology"},{"issue":"4","key":"10357_CR10","doi-asserted-by":"publisher","first-page":"CD012663","DOI":"10.1002\/14651858.CD012663.pub2","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost, F. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., et al. (2019). Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 4(4), CD012663. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10357_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.euo.2024.06.009","volume":"7","author":"D Tilki","year":"2024","unstructured":"Tilki, D., Chen, M. H., Huland, H., Graefen, M., & D\u2019Amico, A. V. (2024). Mortality risk for patients with biopsy Gleason grade group 1 prostate cancer. Eur Urol Oncol., 7(6), 1520\u20131526. https:\/\/doi.org\/10.1016\/j.euo.2024.06.009","journal-title":"Eur Urol Oncol."},{"issue":"4","key":"10357_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1159\/000437170","volume":"95","author":"B Helpap","year":"2015","unstructured":"Helpap, B., Ringli, D., Breul, J., Tonhauser, J., Poser, I., & Seifert, H. H. (2015). The value of prognostic grouping of prostatic carcinomas for urologists and pathologists. Urologia Internationalis, 95(4), 436\u2013444. https:\/\/doi.org\/10.1159\/000437170","journal-title":"Urologia Internationalis"},{"issue":"4\u20135","key":"10357_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.euf.2016.10.010","volume":"3","author":"CJ Kane","year":"2017","unstructured":"Kane, C. J., Eggener, S. E., Shindel, A. W., & Andriole, G. L. (2017). Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2\u20133) and implications for risk stratification: A systematic review. European urology focus., 3(4\u20135), 487\u2013497. https:\/\/doi.org\/10.1016\/j.euf.2016.10.010","journal-title":"European urology focus."},{"issue":"5b","key":"10357_CR14","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1111\/bju.13903","volume":"120","author":"ZS Zumsteg","year":"2017","unstructured":"Zumsteg, Z. S., Zelefsky, M. J., Woo, K. M., Spratt, D. E., Kollmeier, M. A., McBride, S., et al. (2017). Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. BJU International, 120(5b), E87-e95. https:\/\/doi.org\/10.1111\/bju.13903","journal-title":"BJU International"},{"issue":"2","key":"10357_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/pros.23255","volume":"77","author":"ZS Zumsteg","year":"2017","unstructured":"Zumsteg, Z. S., Chen, Z., Howard, L. E., Amling, C. L., Aronson, W. J., Cooperberg, M. R., et al. (2017). Number of unfavorable intermediate-risk factors predicts pathologic upstaging and prostate cancer-specific mortality following radical prostatectomy: Results from the SEARCH database. Prostate, 77(2), 154\u2013163. https:\/\/doi.org\/10.1002\/pros.23255","journal-title":"Prostate"},{"issue":"4","key":"10357_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2016","unstructured":"Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., & Auman, J. T. (2016). The molecular taxonomy of primary prostate cancer. Cell, 163(4), 1011\u20131025. https:\/\/doi.org\/10.1016\/j.cell.2015.10.025","journal-title":"Cell"},{"issue":"6","key":"10357_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., et al. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 23(6), 703\u2013713. https:\/\/doi.org\/10.1038\/nm.4333","journal-title":"Nature Medicine"},{"issue":"10","key":"10357_CR18","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ijc.35279","volume":"156","author":"CB McGrath","year":"2025","unstructured":"McGrath, C. B., Shreves, A. H., Shanahan, M. R., Guard, H. E., Nhliziyo, M. V., Pernar, C. H., et al. (2025). Etiology of prostate cancer with the TMPRSS2: ERG fusion: A systematic review of risk factors. International Journal of Cancer, 156(10), 1898\u20131908. https:\/\/doi.org\/10.1002\/ijc.35279","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10357_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.5858\/arpa.2011-0424-OA","volume":"136","author":"SA Tomlins","year":"2012","unstructured":"Tomlins, S. A., Palanisamy, N., Siddiqui, J., Chinnaiyan, A. M., & Kunju, L. P. (2012). Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Archives of Pathology and Laboratory Medicine, 136(8), 935\u2013946. https:\/\/doi.org\/10.5858\/arpa.2011-0424-OA","journal-title":"Archives of Pathology and Laboratory Medicine"},{"issue":"10","key":"10357_CR20","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41417-022-00454-5","volume":"29","author":"L Fang","year":"2022","unstructured":"Fang, L., Li, D., Yin, J., Pan, H., Ye, H., Bowman, J., et al. (2022). TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence. Cancer Gene Therapy, 29(10), 1463\u20131476. https:\/\/doi.org\/10.1038\/s41417-022-00454-5","journal-title":"Cancer Gene Therapy"},{"issue":"11","key":"10357_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00432-018-2730-5","volume":"144","author":"TA Bismar","year":"2018","unstructured":"Bismar, T. A., Hegazy, S., Feng, Z., Yu, D., Donnelly, B., Palanisamy, N., et al. (2018). Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: A proposed method for risk stratification. Journal of Cancer Research and Clinical Oncology, 144(11), 2117\u20132125. https:\/\/doi.org\/10.1007\/s00432-018-2730-5","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"10357_CR22","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1038\/s41467-021-24380-6","volume":"12","author":"M Zoma","year":"2021","unstructured":"Zoma, M., Curti, L., Shinde, D., Albino, D., Mitra, A., Sgrignani, J., et al. (2021). EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nature Communications, 12(1), 4147. https:\/\/doi.org\/10.1038\/s41467-021-24380-6","journal-title":"Nature Communications"},{"issue":"2","key":"10357_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086824","volume":"9","author":"C H\u00e4ggl\u00f6f","year":"2014","unstructured":"H\u00e4ggl\u00f6f, C., Hammarsten, P., Str\u00f6mvall, K., Egevad, L., Josefsson, A., Stattin, P., et al. (2014). TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE,9(2), Article e86824. https:\/\/doi.org\/10.1371\/journal.pone.0086824","journal-title":"PLoS ONE"},{"key":"10357_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12935-018-0672-2","volume":"18","author":"C Song","year":"2018","unstructured":"Song, C., & Chen, H. (2018). Predictive significance of TMRPSS2-ERG fusion in prostate cancer: A meta-analysis. Cancer Cell International, 18, 177. https:\/\/doi.org\/10.1186\/s12935-018-0672-2","journal-title":"Cancer Cell International"},{"issue":"1","key":"10357_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., et al. (2016). Urine TMPRSS2: ERG Plus PCA3 for individualized prostate cancer risk assessment. European Urology, 70(1), 45\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039","journal-title":"European Urology"},{"issue":"2","key":"10357_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.clgc.2015.12.001","volume":"14","author":"F Sanguedolce","year":"2016","unstructured":"Sanguedolce, F., Cormio, A., Brunelli, M., D\u2019Amuri, A., Carrieri, G., Bufo, P., et al. (2016). Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: Literature review. Clinical Genitourinary Cancer, 14(2), 117\u2013121. https:\/\/doi.org\/10.1016\/j.clgc.2015.12.001","journal-title":"Clinical Genitourinary Cancer"},{"issue":"12","key":"10357_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pros.24921","volume":"85","author":"M Oderda","year":"2025","unstructured":"Oderda, M., Orlando, G., Calleris, G., Capella, G., Delsedime, L., Duregon, E., et al. (2025). Role of cell-cycle proliferation test, triple hit phenotype, and TMPRSS2-ERG expression to evaluate the risk of progression in prostate cancer patients under active surveillance. Prostate, 85(12), 1104\u20131113. https:\/\/doi.org\/10.1002\/pros.24921","journal-title":"Prostate"},{"key":"10357_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04016-7","author":"I Henriquez","year":"2025","unstructured":"Henriquez, I., Malave, B., Benitez-Gabella, G., Parada, D., Canela, M., Garc\u00eda-Pablo, R., et al. (2025). ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy. Clinical and Translational Oncology. https:\/\/doi.org\/10.1007\/s12094-025-04016-7","journal-title":"Clinical and Translational Oncology"},{"issue":"4","key":"10357_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pros.24469","volume":"83","author":"MP Fernandez-Perez","year":"2023","unstructured":"Fernandez-Perez, M. P., Perez-Navarro, E., Alonso-Gordoa, T., Conteduca, V., Font, A., V\u00e1zquez-Est\u00e9vez, S., et al. (2023). A correlative biomarker study and integrative prognostic model in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with enzalutamide. Prostate, 83(4), 376\u2013384. https:\/\/doi.org\/10.1002\/pros.24469","journal-title":"Prostate"},{"issue":"2","key":"10357_CR30","doi-asserted-by":"publisher","first-page":"e1728","DOI":"10.1002\/cnr2.1728","volume":"6","author":"YY Segura-Moreno","year":"2023","unstructured":"Segura-Moreno, Y. Y., Sanabria-Salas, M. C., Mesa-L\u00f3pez De Mesa, J. A., Varela-Ramirez, R., Acosta-Vega, N. L., & Serrano, M. L. (2023). Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer. Cancer Rep (Hoboken), 6(2), e1728. https:\/\/doi.org\/10.1002\/cnr2.1728","journal-title":"Cancer Rep (Hoboken)"},{"issue":"5","key":"10357_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., et al. (2018). The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 50(5), 645\u2013651. https:\/\/doi.org\/10.1038\/s41588-018-0078-z","journal-title":"Nature Genetics"},{"issue":"7801","key":"10357_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., et al. (2020). A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature, 580(7801), 93\u201399. https:\/\/doi.org\/10.1038\/s41586-020-2135-x","journal-title":"Nature"},{"issue":"11","key":"10357_CR33","doi-asserted-by":"publisher","first-page":"e70979","DOI":"10.1002\/cam4.70979","volume":"14","author":"CT Cobbs","year":"2025","unstructured":"Cobbs, C. T., Chesnut, G. T., & Shafi, A. A. (2025). Understanding racial disparities in prostate cancer: A multifaceted approach. Cancer Med, 14(11), e70979. https:\/\/doi.org\/10.1002\/cam4.70979","journal-title":"Cancer Med"},{"key":"10357_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-00949-w","author":"EM Feng","year":"2025","unstructured":"Feng, E. M., Vo-Phamhi, J., Subramanian, A. N., Dias, M., Foye, A., Vinson, J., et al. (2025). Racial variation in the advanced prostate cancer genome. Prostate Cancer and Prostatic Diseases. https:\/\/doi.org\/10.1038\/s41391-025-00949-w","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"17","key":"10357_CR35","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.Ccr-19-4112","volume":"26","author":"Y Koga","year":"2020","unstructured":"Koga, Y., Song, H., Chalmers, Z. R., Newberg, J., Kim, E., Carrot-Zhang, J., et al. (2020). Genomic profiling of prostate cancers from men with african and european ancestry. Clinical Cancer Research, 26(17), 4651\u20134660. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-4112","journal-title":"Clinical Cancer Research"},{"issue":"7766","key":"10357_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","volume":"571","author":"G Cavalli","year":"2019","unstructured":"Cavalli, G., & Heard, E. (2019). Advances in epigenetics link genetics to the environment and disease. Nature, 571(7766), 489\u2013499. https:\/\/doi.org\/10.1038\/s41586-019-1411-0","journal-title":"Nature"},{"issue":"5","key":"10357_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D., Van Allen, E. M., Wu, Y. M., Schultz, N., Lonigro, R. J., Mosquera, J. M., et al. (2015). Integrative clinical genomics of advanced prostate cancer. Cell, 161(5), 1215\u20131228. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001","journal-title":"Cell"},{"issue":"11","key":"10357_CR38","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.molmed.2019.07.001","volume":"25","author":"V Bhatia","year":"2019","unstructured":"Bhatia, V., & Ateeq, B. (2019). Molecular underpinnings governing genetic complexity of ETS-fusion-negative prostate cancer. Trends in Molecular Medicine, 25(11), 1024\u20131038. https:\/\/doi.org\/10.1016\/j.molmed.2019.07.001","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10357_CR39","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","volume":"13","author":"N Besselink","year":"2023","unstructured":"Besselink, N., Keijer, J., Vermeulen, C., Boymans, S., de Ridder, J., van Hoeck, A., et al. (2023). The genome-wide mutational consequences of DNA hypomethylation. Science and Reports,13(1), 6874. https:\/\/doi.org\/10.1038\/s41598-023-33932-3","journal-title":"Science and Reports"},{"issue":"1","key":"10357_CR40","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1038\/s41598-021-91037-1","volume":"11","author":"MD Long","year":"2021","unstructured":"Long, M. D., Dhiman, V. K., Affronti, H. C., Hu, Q., Liu, S., & Smiraglia, D. J. (2021). Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. Science and Reports, 11(1), 11405. https:\/\/doi.org\/10.1038\/s41598-021-91037-1","journal-title":"Science and Reports"},{"issue":"1","key":"10357_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3892\/mmr.2015.3402","volume":"12","author":"W Zhang","year":"2015","unstructured":"Zhang, W., Jiao, H., Zhang, X., Zhao, R., Wang, F., He, W., et al. (2015). Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer. Molecular Medicine Reports, 12(1), 141\u2013146. https:\/\/doi.org\/10.3892\/mmr.2015.3402","journal-title":"Molecular Medicine Reports"},{"issue":"5","key":"10357_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","volume":"46","author":"R Henrique","year":"2004","unstructured":"Henrique, R., & Jer\u00f3nimo, C. (2004). Molecular detection of prostate cancer: A role for GSTP1 hypermethylation. Eur Urol, 46(5), 660\u2013669. https:\/\/doi.org\/10.1016\/j.eururo.2004.06.014. discussion 9.","journal-title":"Eur Urol"},{"issue":"22","key":"10357_CR43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/jnci\/93.22.1747","volume":"93","author":"C Jer\u00f3nimo","year":"2001","unstructured":"Jer\u00f3nimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W. G., et al. (2001). Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. Journal of the National Cancer Institute, 93(22), 1747\u20131752. https:\/\/doi.org\/10.1093\/jnci\/93.22.1747","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10357_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.22037\/uj.v20i.8014","volume":"21","author":"E Aykanli","year":"2024","unstructured":"Aykanli, E., Arisan, S., Arisan, E. D., & Yavuzsan, A. H. (2024). Diagnostic value of GSTP1, RASSF1, and RASSF2 methylation in serum of prostate cancer patients. Urology Journal,21(3), 182\u2013188. https:\/\/doi.org\/10.22037\/uj.v20i.8014","journal-title":"Urology Journal"},{"issue":"9","key":"10357_CR45","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/bjc.2014.463","volume":"111","author":"KL Mahon","year":"2014","unstructured":"Mahon, K. L., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R. J., et al. (2014). Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802\u20131809. https:\/\/doi.org\/10.1038\/bjc.2014.463","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10357_CR46","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.Cd-12-0041","volume":"2","author":"ST B\u00f6rno","year":"2012","unstructured":"B\u00f6rno, S. T., Fischer, A., Kerick, M., F\u00e4lth, M., Laible, M., Brase, J. C., et al. (2012). Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discovery, 2(11), 1024\u20131035. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0041","journal-title":"Cancer Discovery"},{"issue":"1","key":"10357_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12885-017-3252-2","volume":"17","author":"MK Kirby","year":"2017","unstructured":"Kirby, M. K., Ramaker, R. C., Roberts, B. S., Lasseigne, B. N., Gunther, D. S., Burwell, T. C., et al. (2017). Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer, 17(1), 273. https:\/\/doi.org\/10.1186\/s12885-017-3252-2","journal-title":"BMC Cancer"},{"issue":"1","key":"10357_CR48","doi-asserted-by":"publisher","first-page":"9174","DOI":"10.1038\/s41467-025-64213-4","volume":"16","author":"V Rosti","year":"2025","unstructured":"Rosti, V., Lembo, G., Petrini, C., Gorini, F., Quadri, R., Cordiglieri, C., et al. (2025). Chromatin remodeling restrains oncogenic functions in prostate cancer. Nature Communications, 16(1), 9174. https:\/\/doi.org\/10.1038\/s41467-025-64213-4","journal-title":"Nature Communications"},{"issue":"1","key":"10357_CR49","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41467-019-08302-1","volume":"10","author":"Q Du","year":"2019","unstructured":"Du, Q., Bert, S. A., Armstrong, N. J., Caldon, C. E., Song, J. Z., Nair, S. S., et al. (2019). Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer. Nature Communications, 10(1), 416. https:\/\/doi.org\/10.1038\/s41467-019-08302-1","journal-title":"Nature Communications"},{"issue":"1","key":"10357_CR50","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","volume":"9","author":"S Stelloo","year":"2018","unstructured":"Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., et al. (2018). Integrative epigenetic taxonomy of primary prostate cancer. Nature Communications, 9(1), 4900. https:\/\/doi.org\/10.1038\/s41467-018-07270-2","journal-title":"Nature Communications"},{"issue":"4","key":"10357_CR51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello, M. A., Liu, D., Deonarine, L. D., Robinson, B. D., Huang, D., Stelloo, S., et al. (2019). CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell, 35(4), 603-617.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.03.001","journal-title":"Cancer Cell"},{"issue":"1","key":"10357_CR52","doi-asserted-by":"publisher","first-page":"7292","DOI":"10.1038\/s41467-021-27615-8","volume":"12","author":"SE Eksi","year":"2021","unstructured":"Eksi, S. E., Chitsazan, A., Sayar, Z., Thomas, G. V., Fields, A. J., Kopp, R. P., et al. (2021). Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. Nature Communications, 12(1), 7292. https:\/\/doi.org\/10.1038\/s41467-021-27615-8","journal-title":"Nature Communications"},{"issue":"9","key":"10357_CR53","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.3930","volume":"49","author":"KJ Kron","year":"2017","unstructured":"Kron, K. J., Murison, A., Zhou, S., Huang, V., Yamaguchi, T. N., Shiah, Y. J., et al. (2017). TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics, 49(9), 1336\u20131345. https:\/\/doi.org\/10.1038\/ng.3930","journal-title":"Nature Genetics"},{"issue":"4","key":"10357_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/onc.2015.109","volume":"35","author":"P Adamo","year":"2016","unstructured":"Adamo, P., & Ladomery, M. R. (2016). The oncogene ERG: A key factor in prostate cancer. Oncogene, 35(4), 403\u2013414. https:\/\/doi.org\/10.1038\/onc.2015.109","journal-title":"Oncogene"},{"key":"10357_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/rru.S388265","volume":"17","author":"A Quistini","year":"2025","unstructured":"Quistini, A., Chierigo, F., Fallara, G., Depalma, M., Tozzi, M., Maggi, M., et al. (2025). Androgen receptor signalling in prostate cancer: Mechanisms of resistance to endocrine therapies. Res Rep Urol., 17, 211\u2013223. https:\/\/doi.org\/10.2147\/rru.S388265","journal-title":"Res Rep Urol."},{"issue":"6320","key":"10357_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C. C., et al. (2017). SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science, 355(6320), 84\u201388. https:\/\/doi.org\/10.1126\/science.aah4307","journal-title":"Science"},{"issue":"2","key":"10357_CR57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","volume":"138","author":"Q Wang","year":"2009","unstructured":"Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138(2), 245\u2013256. https:\/\/doi.org\/10.1016\/j.cell.2009.04.056","journal-title":"Cell"},{"key":"10357_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2017.08.004","volume":"51","author":"A Chatterjee","year":"2018","unstructured":"Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018). Epigenetic drivers of tumourigenesis and cancer metastasis. Seminars in Cancer Biology, 51, 149\u2013159. https:\/\/doi.org\/10.1016\/j.semcancer.2017.08.004","journal-title":"Seminars in Cancer Biology"},{"issue":"21","key":"10357_CR59","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1158\/0008-5472.Can-07-6088","volume":"68","author":"S Yegnasubramanian","year":"2008","unstructured":"Yegnasubramanian, S., Haffner, M. C., Zhang, Y., Gurel, B., Cornish, T. C., Wu, Z., et al. (2008). DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Research, 68(21), 8954\u20138967. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6088","journal-title":"Cancer Research"},{"issue":"8","key":"10357_CR60","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sj\u00f6str\u00f6m, M., et al. (2020). The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 52(8), 778\u2013789. https:\/\/doi.org\/10.1038\/s41588-020-0648-8","journal-title":"Nature Genetics"},{"key":"10357_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal2380","author":"WA Flavahan","year":"2017","unstructured":"Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science. https:\/\/doi.org\/10.1126\/science.aal2380","journal-title":"Science"},{"issue":"6320","key":"10357_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., et al. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 355(6320), 78\u201383. https:\/\/doi.org\/10.1126\/science.aah4199","journal-title":"Science"},{"issue":"9","key":"10357_CR63","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies, A., Nouruzi, S., Ganguli, D., Namekawa, T., Thaper, D., Linder, S., et al. (2021). An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 23(9), 1023\u20131034. https:\/\/doi.org\/10.1038\/s41556-021-00743-5","journal-title":"Nature Cell Biology"},{"issue":"5","key":"10357_CR64","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., et al. (2016). Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. European Urology, 70(5), 740\u2013748. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.012","journal-title":"European Urology"},{"issue":"7","key":"10357_CR65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan, J., Donovan, M. J., O\u2019Neill, V., Bentink, S., Noerholm, M., Belzer, S., et al. (2016). A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncology, 2(7), 882\u2013889. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097","journal-title":"JAMA Oncology"},{"issue":"6","key":"10357_CR66","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","volume":"10","author":"JJ Tosoian","year":"2024","unstructured":"Tosoian, J. J., Zhang, Y., Xiao, L., Xie, C., Samora, N. L., Niknafs, Y. S., et al. (2024). Development and validation of an 18-gene urine test for high-grade prostate cancer. JAMA Oncology, 10(6), 726\u2013736. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0455","journal-title":"JAMA Oncology"},{"issue":"1","key":"10357_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41391-023-00766-z","volume":"28","author":"MJ Boyer","year":"2025","unstructured":"Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., et al. (2025). Genomic classifiers and prognosis of localized prostate cancer: A systematic review. Prostate Cancer and Prostatic Diseases, 28(1), 103\u2013111. https:\/\/doi.org\/10.1038\/s41391-023-00766-z","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"6","key":"10357_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066855","volume":"8","author":"N Erho","year":"2013","unstructured":"Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., et al. (2013). Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE, 8(6), Article e66855. https:\/\/doi.org\/10.1371\/journal.pone.0066855","journal-title":"PLoS ONE"},{"issue":"3","key":"10357_CR69","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","volume":"66","author":"EA Klein","year":"2014","unstructured":"Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., et al. (2014). A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urology, 66(3), 550\u2013560. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.004","journal-title":"European Urology"},{"issue":"3","key":"10357_CR70","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s1470-2045(10)70295-3","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., et al. (2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncology, 12(3), 245\u2013255. https:\/\/doi.org\/10.1016\/s1470-2045(10)70295-3","journal-title":"Lancet Oncology"},{"key":"10357_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03704-9","author":"EM Kwan","year":"2025","unstructured":"Kwan, E. M., Ng, S. W. S., Tolmeijer, S. H., Emmett, L., Sandhu, S., Buteau, J. P., et al. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: Circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine. https:\/\/doi.org\/10.1038\/s41591-025-03704-9","journal-title":"Nature Medicine"},{"issue":"1","key":"10357_CR72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.Ccr-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., et al. (2023). Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clinical Cancer Research, 29(1), 81\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0931","journal-title":"Clinical Cancer Research"},{"issue":"16","key":"10357_CR73","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1158\/1078-0432.Ccr-21-1625","volume":"27","author":"M Annala","year":"2021","unstructured":"Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G., Beja, K., Sipola, J., et al. (2021). Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition. Clinical Cancer Research, 27(16), 4610\u20134623. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1625","journal-title":"Clinical Cancer Research"},{"key":"10357_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.07.011","author":"S Halabi","year":"2025","unstructured":"Halabi, S., Guo, S., Luo, B., Yu, C., Knutson, T. P., Kobilka, A., et al. (2025). Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer. European Urology. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.011","journal-title":"European Urology"},{"key":"10357_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01343-y","author":"AL Riediger","year":"2026","unstructured":"Riediger, A. L., Eickelschulte, S., Janke, F., Janscho, D., Lazareva, O., H\u00fcbschmann, D., et al. (2026). Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancer. NPJ Precision Oncology. https:\/\/doi.org\/10.1038\/s41698-026-01343-y","journal-title":"NPJ Precision Oncology"},{"key":"10357_CR76","doi-asserted-by":"publisher","unstructured":"Kim, D.-W., Jung, M.-H., Cho, H., Cha, J., Han, K.-H., Choi, J. H., et al. Plasma circulating tumor DNA methylation enables non-invasive disease stratification beyond PSA in prostate cancer. Prostate International. https:\/\/doi.org\/10.1016\/j.prnil.2026.05.002","DOI":"10.1016\/j.prnil.2026.05.002"},{"key":"10357_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104699","volume":"210","author":"S Plas","year":"2025","unstructured":"Plas, S., Melchior, F., Aigner, G. P., Frantzi, M., Pencik, J., Kafka, M., et al. (2025). The impact of urine biomarkers for prostate cancer detection-A systematic state of the art review. Critical Reviews in Oncology Hematology, 210, Article 104699. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104699","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"10357_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-026-00977-9","author":"A Chatterjee","year":"2026","unstructured":"Chatterjee, A., & Rodger, E. J. (2026). Written in blood: DNA methylation in liquid biopsy. Nature reviews genetics. https:\/\/doi.org\/10.1038\/s41576-026-00977-9","journal-title":"Nature reviews genetics."},{"issue":"1","key":"10357_CR79","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen, S., Petricca, J., Ye, W., Guan, J., Zeng, Y., Cheng, N., et al. (2022). The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nature Communications, 13(1), 6467. https:\/\/doi.org\/10.1038\/s41467-022-34012-2","journal-title":"Nature Communications"},{"issue":"1","key":"10357_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05728-9","volume":"43","author":"Z Han","year":"2025","unstructured":"Han, Z., Zhao, Y., Tang, Y., Yi, X., Li, J., Li, X., et al. (2025). Liquid biopsy for promoter methylation in prostate cancer: A promising non-invasive diagnostic weapon. World Journal of Urology, 43(1), Article 353. https:\/\/doi.org\/10.1007\/s00345-025-05728-9","journal-title":"World Journal of Urology"},{"issue":"4","key":"10357_CR81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4132\/jptm.2025.04.16","volume":"59","author":"JC Prihadi","year":"2025","unstructured":"Prihadi, J. C., Lionardi, S. K., Widjanarko, N. D., Alvianto, S., Rinaldi, F. X., & Iskandar, A. F. (2025). AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: A systematic review and meta-analysis. J Pathol Transl Med., 59(4), 235\u2013248. https:\/\/doi.org\/10.4132\/jptm.2025.04.16","journal-title":"J Pathol Transl Med."},{"key":"10357_CR82","doi-asserted-by":"publisher","unstructured":"Andarawi, M. O., Otifi, H., Hassan, H., Yousif, A. A., Mustafa, S. A., Elsiddig, S. A., et al. (2025). Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups. European Journal of Histochemistry, 69(1). https:\/\/doi.org\/10.4081\/ejh.2025.4172","DOI":"10.4081\/ejh.2025.4172"},{"issue":"7","key":"10357_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068162","volume":"8","author":"L Richiardi","year":"2013","unstructured":"Richiardi, L., Fiano, V., Grasso, C., Zugna, D., Delsedime, L., Gillio-Tos, A., et al. (2013). Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS ONE, 8(7), Article e68162. https:\/\/doi.org\/10.1371\/journal.pone.0068162","journal-title":"PLoS ONE"},{"issue":"10","key":"10357_CR84","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.celrep.2015.10.078","volume":"13","author":"JM Bhasin","year":"2015","unstructured":"Bhasin, J. M., Lee, B. H., Matkin, L., Taylor, M. G., Hu, B., Xu, Y., et al. (2015). Methylome-wide sequencing detects DNA hypermethylation distinguishing indolent from aggressive prostate cancer. Cell Reports, 13(10), 2135\u20132146. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.078","journal-title":"Cell Reports"},{"issue":"27","key":"10357_CR85","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/jco.21.02741","volume":"40","author":"WC Jackson","year":"2022","unstructured":"Jackson, W. C., Tang, M., Schipper, M. J., Sandler, H. M., Zumsteg, Z. S., Efstathiou, J. A., et al. (2022). Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: Analysis of NRG oncology\/RTOG 9601. Journal of Clinical Oncology, 40(27), 3172\u20133179. https:\/\/doi.org\/10.1200\/jco.21.02741","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"10357_CR86","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1200\/jco.2016.70.7794","volume":"35","author":"P Rajan","year":"2017","unstructured":"Rajan, P., Sooriakumaran, P., Nyberg, T., Akre, O., Carlsson, S., Egevad, L., et al. (2017). Effect of comorbidity on prostate cancer-specific mortality: A prospective observational study. Journal of Clinical Oncology, 35(31), 3566\u20133574. https:\/\/doi.org\/10.1200\/jco.2016.70.7794","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10357_CR87","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/pros.24108","volume":"81","author":"TK Lehto","year":"2021","unstructured":"Lehto, T. K., St\u00fcrenberg, C., Mal\u00e9n, A., Erickson, A. M., Koistinen, H., Mills, I. G., et al. (2021). Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2\u20134 prostate cancers. Prostate, 81(7), 368\u2013376. https:\/\/doi.org\/10.1002\/pros.24108","journal-title":"Prostate"},{"issue":"1","key":"10357_CR88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.euo.2023.06.002","volume":"7","author":"A Sood","year":"2024","unstructured":"Sood, A., Kishan, A. U., Evans, C. P., Feng, F. Y., Morgan, T. M., Murphy, D. G., et al. (2024). The impact of positron emission tomography imaging and tumor molecular profiling on risk stratification, treatment choice, and oncological outcomes of patients with primary or relapsed prostate cancer: An international collaborative review of the existing literature. Eur Urol Oncol., 7(1), 27\u201343. https:\/\/doi.org\/10.1016\/j.euo.2023.06.002","journal-title":"Eur Urol Oncol."},{"issue":"1","key":"10357_CR89","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijrobp.2018.08.030","volume":"103","author":"A Berlin","year":"2019","unstructured":"Berlin, A., Murgic, J., Hosni, A., Pintilie, M., Salcedo, A., Fraser, M., et al. (2019). Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy. International Journal of Radiation Oncology, Biology, Physics, 103(1), 84\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.030","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10357_CR90","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2016.01.008","volume":"70","author":"SJ Freedland","year":"2016","unstructured":"Freedland, S. J., Choeurng, V., Howard, L., De Hoedt, A., du Plessis, M., Yousefi, K., et al. (2016). Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. European Urology, 70(4), 588\u2013596. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.008","journal-title":"European Urology"},{"issue":"2","key":"10357_CR91","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7326\/annals-24-00700","volume":"178","author":"AA Tabriz","year":"2025","unstructured":"Tabriz, A. A., Boyer, M. J., Gordon, A. M., Carpenter, D. J., Gingrich, J. R., Raman, S. R., et al. (2025). Impact of genomic classifiers on risk stratification and treatment intensity in patients with localized prostate cancer: A systematic review. Annals of Internal Medicine, 178(2), 218\u2013228. https:\/\/doi.org\/10.7326\/annals-24-00700","journal-title":"Annals of Internal Medicine"},{"issue":"16","key":"10357_CR92","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/pros.24072","volume":"80","author":"NY Greenland","year":"2020","unstructured":"Greenland, N. Y., Cowan, J. E., Chan, E., Carroll, P. R., Stohr, B. A., & Simko, J. P. (2020). Prostate biopsy histopathologic features correlate with a commercial gene expression assay\u2019s reclassification of patient NCCN risk category. Prostate, 80(16), 1421\u20131428. https:\/\/doi.org\/10.1002\/pros.24072","journal-title":"Prostate"},{"issue":"6","key":"10357_CR93","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.urpr.2015.02.007","volume":"2","author":"MA Dall\u2019Era","year":"2015","unstructured":"Dall\u2019Era, M. A., Maddala, T., Polychronopoulos, L., Gallagher, J. R., Febbo, P. G., & Denes, B. S. (2015). Utility of the oncotype DX(\u00ae) prostate cancer assay in clinical practice for treatment selection in men newly diagnosed with prostate cancer: A retrospective chart review analysis. Urology Practice, 2(6), 343\u2013348. https:\/\/doi.org\/10.1016\/j.urpr.2015.02.007","journal-title":"Urology Practice"},{"key":"10357_CR94","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00705","volume":"9","author":"AY Jia","year":"2025","unstructured":"Jia, A. Y., Sun, Y., Patel, M., Baydoun, A., Vince, R. A., Shoag, J. E., et al. (2025). Cross-comparison individual patient-level analysis of three gene expression signatures in localized prostate in over 50,000 men. JCO Precision Oncology, 9, Article e2400705. https:\/\/doi.org\/10.1200\/po-24-00705","journal-title":"JCO Precision Oncology"},{"issue":"2","key":"10357_CR95","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41391-020-00305-0","volume":"24","author":"M Shahait","year":"2021","unstructured":"Shahait, M., Alshalalfa, M., Nguyen, P. L., Al-Fahmawi, A., Dobbs, R. W., Lal, P., et al. (2021). Correlative analysis between two commercially available post-prostatectomy genomic tests. Prostate Cancer and Prostatic Diseases, 24(2), 575\u2013577. https:\/\/doi.org\/10.1038\/s41391-020-00305-0","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10357_CR96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2017.05.028","volume":"107","author":"JV Hegde","year":"2017","unstructured":"Hegde, J. V., Veruttipong, D., Said, J. W., Reiter, R. E., Steinberg, M. L., King, C. R., et al. (2017). Prostate cancer antigen 3 score does not predict for adverse pathologic features at radical prostatectomy or for progression-free survival in clinically localized, intermediate- and high-risk prostate cancer. Urology, 107, 171\u2013177. https:\/\/doi.org\/10.1016\/j.urology.2017.05.028","journal-title":"Urology"},{"issue":"4","key":"10357_CR97","doi-asserted-by":"publisher","first-page":"163.e15","DOI":"10.1016\/j.urolonc.2014.12.002","volume":"33","author":"F Cantiello","year":"2015","unstructured":"Cantiello, F., Russo, G. I., Ferro, M., Cicione, A., Cimino, S., Favilla, V., et al. (2015). Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy. Urologic Oncology, 33(4), 163.e15-16323. https:\/\/doi.org\/10.1016\/j.urolonc.2014.12.002","journal-title":"Urologic Oncology"},{"issue":"6","key":"10357_CR98","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/ju.0000000000000704","volume":"203","author":"S Pak","year":"2020","unstructured":"Pak, S., Suh, Y. S., Lee, D. E., Kim, S. H., Joung, J. Y., Park, W. S., et al. (2020). Association between postoperative detection of circulating tumor cells and recurrence in patients with prostate cancer. Journal of Urology,203(6), 1128\u20131134. https:\/\/doi.org\/10.1097\/ju.0000000000000704","journal-title":"Journal of Urology"},{"issue":"7","key":"10357_CR99","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/meg.0000000000001373","volume":"31","author":"Z Li","year":"2019","unstructured":"Li, Z., Xiao, D., Li, X., Zhan, P., Wang, J., & Zhang, H. (2019). Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. European Journal of Gastroenterology and Hepatology,31(7), 885\u2013892. https:\/\/doi.org\/10.1097\/meg.0000000000001373","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10357_CR100","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21873\/cdp.10106","volume":"2","author":"A Bera","year":"2022","unstructured":"Bera, A., Russ, E., Karaian, J., Landa, A., Radhakrishnan, S., Subramanian, M., et al. (2022). Circulating cell-free DNA in serum as a marker for the early detection of tumor recurrence in breast cancer patients. Cancer Diagnosis and Prognosis, 2(3), 285\u2013292. https:\/\/doi.org\/10.21873\/cdp.10106","journal-title":"Cancer Diagnosis and Prognosis"},{"issue":"5","key":"10357_CR101","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s13277-013-0854-4","volume":"34","author":"ML Wroclawski","year":"2013","unstructured":"Wroclawski, M. L., Serpa-Neto, A., Fonseca, F. L., Castro-Neves-Neto, O., Pompeo, A. S., Machado, M. T., et al. (2013). Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biology, 34(5), 2921\u20132927. https:\/\/doi.org\/10.1007\/s13277-013-0854-4","journal-title":"Tumour Biology"},{"issue":"3","key":"10357_CR102","doi-asserted-by":"publisher","first-page":"969","DOI":"10.4143\/crt.2022.1557","volume":"55","author":"X Fei","year":"2023","unstructured":"Fei, X., Du, X., Gong, Y., Liu, J., Fan, L., Wang, J., et al. (2023). Early plasma circulating tumor DNA as a potential biomarker of disease recurrence in non-metastatic prostate cancer. Cancer Research and Treatment, 55(3), 969\u2013977. https:\/\/doi.org\/10.4143\/crt.2022.1557","journal-title":"Cancer Research and Treatment"},{"issue":"23","key":"10357_CR103","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., et al. (2019). Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(23), 11428\u201311436. https:\/\/doi.org\/10.1073\/pnas.1902651116","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10357_CR104","doi-asserted-by":"publisher","DOI":"10.1200\/po-25-00341","volume":"9","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri, R., Garraway, I. P., Maxwell, K. N., Rettig, M., Desai, H., Schoen, M. W., et al. (2025). Prognostic significance of RB1 alterations on outcomes in metastatic prostate cancer. JCO Precision Oncology, 9, Article e2500341. https:\/\/doi.org\/10.1200\/po-25-00341","journal-title":"JCO Precision Oncology"},{"issue":"4","key":"10357_CR105","doi-asserted-by":"publisher","first-page":"161.e19","DOI":"10.1016\/j.urolonc.2017.11.001","volume":"36","author":"X Chen","year":"2018","unstructured":"Chen, X., Bernemann, C., Tolkach, Y., Heller, M., Nientiedt, C., Falkenstein, M., et al. (2018). Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urologic Oncology, 36(4), 161.e19. https:\/\/doi.org\/10.1016\/j.urolonc.2017.11.001","journal-title":"Urologic Oncology"},{"issue":"1","key":"10357_CR106","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/modpathol.2017.74","volume":"31","author":"H Li","year":"2018","unstructured":"Li, H., Wang, Z., Xiao, W., Yan, L., Guan, W., Hu, Z., et al. (2018). Androgen-receptor splice variant-7-positive prostate cancer: A novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Modern Pathology, 31(1), 198\u2013208. https:\/\/doi.org\/10.1038\/modpathol.2017.74","journal-title":"Modern Pathology"},{"issue":"11","key":"10357_CR107","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., et al. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine, 371(11), 1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10357_CR108","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","volume":"4","author":"HI Scher","year":"2018","unstructured":"Scher, H. I., Graf, R. P., Schreiber, N. A., Jayaram, A., Winquist, E., McLaughlin, B., et al. (2018). Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncology, 4(9), 1179\u20131186. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1621","journal-title":"JAMA Oncology"},{"issue":"14","key":"10357_CR109","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/1078-0432.Ccr-21-4289","volume":"28","author":"IM Coleman","year":"2022","unstructured":"Coleman, I. M., DeSarkar, N., Morrissey, C., Xin, L., Roudier, M. P., Sayar, E., et al. (2022). Therapeutic implications for intrinsic phenotype classification of metastatic castration-resistant prostate cancer. Clinical Cancer Research, 28(14), 3127\u20133140. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4289","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10357_CR110","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","volume":"7","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal, R., Rydzewski, N. R., Zhang, L., Foye, A., Kim, W., Helzer, K. T., et al. (2021). Prognosis associated with luminal and basal subtypes of metastatic prostate cancer. JAMA Oncology, 7(11), 1644\u20131652. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3987","journal-title":"JAMA Oncology"},{"issue":"8","key":"10357_CR111","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/1078-0432.Ccr-18-3121","volume":"25","author":"SG Zhao","year":"2019","unstructured":"Zhao, S. G., Chen, W. S., Das, R., Chang, S. L., Tomlins, S. A., Chou, J., et al. (2019). Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clinical Cancer Research, 25(8), 2450\u20132457. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3121","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10357_CR112","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., et al. (2017). Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncology, 3(12), 1663\u20131672. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0751","journal-title":"JAMA Oncology"},{"key":"10357_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102728","volume":"54","author":"M Kohli","year":"2020","unstructured":"Kohli, M., Tan, W., Zheng, T., Wang, A., Montesinos, C., Wong, C., et al. (2020). Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. eBioMedicine, 54, Article 102728. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102728","journal-title":"eBioMedicine"},{"key":"10357_CR114","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00029","author":"W Abida","year":"2017","unstructured":"Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., et al. (2017). Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/po.17.00029","journal-title":"JCO Precision Oncology"},{"key":"10357_CR115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu438.20","volume":"25","author":"J Mateo","year":"2014","unstructured":"Mateo, J., Hall, E., Sandhu, S., Omlin, A. G., Miranda, S., Carreira, S., et al. (2014). Antitumour activity of the parp inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (Crpc) in the Toparp trial. Annals of oncology., 25, Article v1. https:\/\/doi.org\/10.1093\/annonc\/mdu438.20","journal-title":"Annals of oncology."},{"key":"10357_CR116","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1038\/ncomms5988","volume":"5","author":"CC Pritchard","year":"2014","unstructured":"Pritchard, C. C., Morrissey, C., Kumar, A., Zhang, X., Smith, C., Coleman, I., et al. (2014). Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nature Communications, 5, 4988. https:\/\/doi.org\/10.1038\/ncomms5988","journal-title":"Nature Communications"},{"issue":"3","key":"10357_CR117","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.21873\/anticanres.17501","volume":"45","author":"J Hirata","year":"2025","unstructured":"Hirata, J., Hara, T., Jimbo, N., Ueki, H., Okamura, Y., Bando, Y., et al. (2025). Genomic profiling of small cell neuroendocrine prostate cancer and its implications for targeted therapies. Anticancer Research, 45(3), 1137\u20131147. https:\/\/doi.org\/10.21873\/anticanres.17501","journal-title":"Anticancer Research"},{"issue":"12","key":"10357_CR118","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/pros.24926","volume":"85","author":"T Fukushima","year":"2025","unstructured":"Fukushima, T., Goto, K., Nakano, Y., Tasaka, S., Iwane, K., Tasaka, R., et al. (2025). Comprehensive genomic profiling testing for castration-resistant prostate cancer in advanced elderly patients: A single-center retrospective cohort study. Prostate, 85(12), 1134\u20131142. https:\/\/doi.org\/10.1002\/pros.24926","journal-title":"Prostate"},{"issue":"5","key":"10357_CR119","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","volume":"37","author":"K Fizazi","year":"2026","unstructured":"Fizazi, K., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., et al. (2026). Advanced and metastatic prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 37(5), 590\u2013607. https:\/\/doi.org\/10.1016\/j.annonc.2026.01.015","journal-title":"Annals of Oncology"},{"key":"10357_CR120","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcancer.2018.01.010","volume":"51","author":"Y Assenov","year":"2018","unstructured":"Assenov, Y., Brocks, D., & Gerh\u00e4user, C. (2018). Intratumor heterogeneity in epigenetic patterns. Seminars in Cancer Biology, 51, 12\u201321. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.010","journal-title":"Seminars in Cancer Biology"},{"issue":"3","key":"10357_CR121","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.euo.2021.02.008","volume":"4","author":"A Erickson","year":"2021","unstructured":"Erickson, A., Hayes, A., Rajakumar, T., Verrill, C., Bryant, R. J., Hamdy, F. C., et al. (2021). A systematic review of prostate cancer heterogeneity: Understanding the clonal ancestry of multifocal disease. Eur Urol Oncol., 4(3), 358\u2013369. https:\/\/doi.org\/10.1016\/j.euo.2021.02.008","journal-title":"Eur Urol Oncol."},{"issue":"3","key":"10357_CR122","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","volume":"75","author":"M L\u00f8vf","year":"2019","unstructured":"L\u00f8vf, M., Zhao, S., Axcrona, U., Johannessen, B., Bakken, A. C., Carm, K. T., et al. (2019). Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. European urology., 75(3), 498\u2013505.","journal-title":"European urology."},{"issue":"3","key":"10357_CR123","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks, D., Assenov, Y., Minner, S., Bogatyrova, O., Simon, R., Koop, C., et al. (2014). Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Reports, 8(3), 798\u2013806. https:\/\/doi.org\/10.1016\/j.celrep.2014.06.053","journal-title":"Cell Reports"},{"issue":"1","key":"10357_CR124","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/modpathol.2012.130","volume":"26","author":"S Minner","year":"2013","unstructured":"Minner, S., G\u00e4rtner, M., Freudenthaler, F., Bauer, M., Kluth, M., Salomon, G., et al. (2013). Marked heterogeneity of ERG expression in large primary prostate cancers. Modern Pathology, 26(1), 106\u2013116. https:\/\/doi.org\/10.1038\/modpathol.2012.130","journal-title":"Modern Pathology"},{"issue":"1","key":"10357_CR125","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner, E. W., Van der Eecken, K., Murtha, A. J., Kwan, E. M., Herberts, C., Sipola, J., et al. (2024). Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nature Cancer, 5(1), 114\u2013130. https:\/\/doi.org\/10.1038\/s43018-023-00692-y","journal-title":"Nature Cancer"},{"issue":"2","key":"10357_CR126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","volume":"71","author":"L Wei","year":"2017","unstructured":"Wei, L., Wang, J., Lampert, E., Schlanger, S., DePriest, A. D., Hu, Q., et al. (2017). Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. European Urology, 71(2), 183\u2013192. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.008","journal-title":"European Urology"},{"key":"10357_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-026-01149-4","author":"A Ali","year":"2026","unstructured":"Ali, A., Mikutenaite, M., Weischenfeldt, J., & Bristow, R. G. (2026). Single-cell and spatial RNA sequencing in prostate cancer. Nature Reviews. Urology. https:\/\/doi.org\/10.1038\/s41585-026-01149-4","journal-title":"Nature Reviews. Urology"},{"issue":"4","key":"10357_CR128","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s10555-024-10193-8","volume":"43","author":"JB Kaushal","year":"2024","unstructured":"Kaushal, J. B., Raut, P., Muniyan, S., Siddiqui, J. A., Alsafwani, Z. W., Seshacharyulu, P., et al. (2024). Racial disparity in prostate cancer: An outlook in genetic and molecular landscape. Cancer and Metastasis Reviews, 43(4), 1233\u20131255. https:\/\/doi.org\/10.1007\/s10555-024-10193-8","journal-title":"Cancer and Metastasis Reviews"},{"issue":"4","key":"10357_CR129","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/bco2.323","volume":"5","author":"KK Sindhu","year":"2024","unstructured":"Sindhu, K. K., Dovey, Z., Thompson, M., Nehlsen, A. D., Skalina, K. A., Malachowska, B., et al. (2024). The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care. BJUI Compass., 5(4), 405\u2013425. https:\/\/doi.org\/10.1002\/bco2.323","journal-title":"BJUI Compass."},{"issue":"1","key":"10357_CR130","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1055-9965.Epi-19-0407","volume":"29","author":"JH Creed","year":"2020","unstructured":"Creed, J. H., Berglund, A. E., Rounbehler, R. J., Awasthi, S., Cleveland, J. L., Park, J. Y., et al. (2020). Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk. Cancer Epidemiology, Biomarkers & Prevention, 29(1), 246\u2013253. https:\/\/doi.org\/10.1158\/1055-9965.Epi-19-0407","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"12","key":"10357_CR131","doi-asserted-by":"publisher","first-page":"e970","DOI":"10.1093\/oncolo\/oyac181","volume":"27","author":"MC Hiemenz","year":"2022","unstructured":"Hiemenz, M. C., Graf, R. P., Schiavone, K., Harries, L., Oxnard, G. R., Ross, J. S., et al. (2022). Real-world comprehensive genomic profiling success rates in tissue and liquid prostate carcinoma specimens. The Oncologist, 27(12), e970\u2013e972. https:\/\/doi.org\/10.1093\/oncolo\/oyac181","journal-title":"The Oncologist"},{"issue":"8","key":"10357_CR132","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.Ccr-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain, M., Corcoran, C., Sibilla, C., Fizazi, K., Saad, F., Shore, N., et al. (2022). Tumor genomic testing for > 4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib). Clinical Cancer Research, 28(8), 1518\u20131530. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3940","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10357_CR133","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00428-017-2213-0","volume":"471","author":"A Guyard","year":"2017","unstructured":"Guyard, A., Boyez, A., Pujals, A., Robe, C., Tran Van Nhieu, J., Allory, Y., et al. (2017). DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks. Virchows Archiv, 471(4), 491\u2013500. https:\/\/doi.org\/10.1007\/s00428-017-2213-0","journal-title":"Virchows Archiv"},{"issue":"1","key":"10357_CR134","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13000-025-01697-0","volume":"20","author":"K Jiang","year":"2025","unstructured":"Jiang, K., Dai, Z., Chen, J., Gao, Z., Tong, H., Liu, H., et al. (2025). Evaluating sensitivity of NGS-based mutation detection across diverse sample types in prostate cancer. Diagnostic Pathology, 20(1), 108. https:\/\/doi.org\/10.1186\/s13000-025-01697-0","journal-title":"Diagnostic Pathology"},{"key":"10357_CR135","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00821","volume":"9","author":"RL Bitting","year":"2025","unstructured":"Bitting, R. L., McNair, C., Wyatt, A. W., Vandekerkhove, G., Choi, T., Leader, A. E., et al. (2025). Factors affecting genomic testing in prostate cancer: Results from the decision-making, experience, and confidence in determining genomic evaluation (DECIDE) survey. JCO Precision Oncology, 9, Article e2400821. https:\/\/doi.org\/10.1200\/po-24-00821","journal-title":"JCO Precision Oncology"},{"key":"10357_CR136","doi-asserted-by":"publisher","unstructured":"De La, O. J., Hoag, J. R., Deem, A. K., Wang, M., Starodynov, A., Udhane, S. S., et al. (2025). Comprehensive genomic profiling of over 10,000 advanced solid tumors. Oncotarget, 16, 587\u2013603. https:\/\/doi.org\/10.18632\/oncotarget.28757","DOI":"10.18632\/oncotarget.28757"},{"issue":"8","key":"10357_CR137","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s12276-024-01288-x","volume":"56","author":"R Kim","year":"2024","unstructured":"Kim, R., Kim, S., Oh, B. B., Yu, W. S., Kim, C. W., Hur, H., et al. (2024). Clinical application of whole-genome sequencing of solid tumors for precision oncology. Experimental & Molecular Medicine, 56(8), 1856\u20131868. https:\/\/doi.org\/10.1038\/s12276-024-01288-x","journal-title":"Experimental & Molecular Medicine"},{"issue":"1","key":"10357_CR138","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/13696998.2024.2329009","volume":"27","author":"JD Ortendahl","year":"2024","unstructured":"Ortendahl, J. D., Cuyun Carter, G., Thakkar, S. G., Bognar, K., Hall, D. W., & Abdou, Y. (2024). Value of next generation sequencing (NGS) testing in advanced cancer patients. Journal of Medical Economics, 27(1), 519\u2013530. https:\/\/doi.org\/10.1080\/13696998.2024.2329009","journal-title":"Journal of Medical Economics"},{"key":"10357_CR139","doi-asserted-by":"publisher","unstructured":"Hu, J. C., Tosoian, J. J., Qi, J., Kaye, D., Johnson, A., Linsell, S., et al. (2018). Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer. JCO Precision Oncology, 2. https:\/\/doi.org\/10.1200\/po.18.00163","DOI":"10.1200\/po.18.00163"},{"issue":"10","key":"10357_CR140","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/cncr.35215","volume":"130","author":"AE Braun","year":"2024","unstructured":"Braun, A. E., Chan, J. M., Neuhaus, J., Cowan, J. E., Kenfield, S. A., Van Blarigan, E. L., et al. (2024). The impact of genomic biomarkers on a clinical risk prediction model for upgrading\/upstaging among men with favorable-risk prostate cancer. Cancer,130(10), 1766\u20131772. https:\/\/doi.org\/10.1002\/cncr.35215","journal-title":"Cancer"},{"issue":"1","key":"10357_CR141","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/bco2.277","volume":"5","author":"MS Leapman","year":"2024","unstructured":"Leapman, M. S., Sutherland, R., Gross, C. P., Ma, X., Seibert, T. M., Cooperberg, M. R., et al. (2024). Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. BJUI Compass, 5(1), 142\u2013149. https:\/\/doi.org\/10.1002\/bco2.277","journal-title":"BJUI Compass"},{"issue":"3","key":"10357_CR142","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., et al. (2024). NCCN guidelines\u00ae insights: Prostate cancer, version 3.2024. J Natl Compr Canc Netw., 22(3), 140\u2013150. https:\/\/doi.org\/10.6004\/jnccn.2024.0019","journal-title":"J Natl Compr Canc Netw."},{"issue":"13","key":"10357_CR143","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/jco.19.02768","volume":"38","author":"SE Eggener","year":"2020","unstructured":"Eggener, S. E., Rumble, R. B., Armstrong, A. J., Morgan, T. M., Crispino, T., Cornford, P., et al. (2020). Molecular biomarkers in localized prostate cancer: ASCO guideline. Journal of Clinical Oncology, 38(13), 1474\u20131494. https:\/\/doi.org\/10.1200\/jco.19.02768","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10357_CR144","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon, R. M., Paik, S., & Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute, 101(21), 1446\u20131452. https:\/\/doi.org\/10.1093\/jnci\/djp335","journal-title":"Journal of the National Cancer Institute"},{"issue":"20","key":"10357_CR145","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/jnci\/djr327","volume":"103","author":"TP Ahern","year":"2011","unstructured":"Ahern, T. P., Hankinson, S. E. (2011) Re: Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute, 103(20), 1558\u20131559.  https:\/\/doi.org\/10.1093\/jnci\/djr327. author reply 9\u201360","journal-title":"Journal of the National Cancer Institute"},{"key":"10357_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.022","author":"N Handa","year":"2025","unstructured":"Handa, N., Li, E. V., Michael, J., Proudfoot, J. A., Weiner, A. B., Alam, R., et al. (2025). Prevalence of potential candidates for targeted therapies according to treatment-related transcriptomic signatures among 140 548 patients with nonmetastatic prostate cancer. European Urology Oncology. https:\/\/doi.org\/10.1016\/j.euo.2025.04.022","journal-title":"European Urology Oncology"},{"issue":"1","key":"10357_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05384-4","volume":"15","author":"A Virga","year":"2025","unstructured":"Virga, A., Urbini, M., Polano, M., Petracci, E., Tedaldi, G., Gurioli, G., et al. (2025). Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA. Scientific Reports, 15(1), Article 21296. https:\/\/doi.org\/10.1038\/s41598-025-05384-4","journal-title":"Scientific Reports"},{"key":"10357_CR148","doi-asserted-by":"publisher","unstructured":"Sailer, V., Eng, K. W., Zhang, T., Bareja, R., Pisapia, D. J., Sigaras, A., et al. (2019). Integrative molecular analysis of patients with advanced and metastatic cancer. JCO Precision Oncology, 3. https:\/\/doi.org\/10.1200\/po.19.00047","DOI":"10.1200\/po.19.00047"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10357-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:34:01Z","timestamp":1784777641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10357-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":148,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10357"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10357-8","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"50"}}